Skip to main navigation
Codiak Biosciences

Investor Relations - Top Nav

  • Our Science

    Our Science

    Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.

    • Exosomes Explained
    • engEx™ Platform
    • Targeted Administration
    • Publications & Presentations
  • Manufacturing
  • Pipeline & Programs

    Pipeline & Programs

    We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.

    • Pipeline
    • exoSTING™
    • exoIL-12™
    • exoASO-STAT6™
  • About Us

    About Us

    At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.

    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Careers
  • Investors & Media

    Investors & Media

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • Investor Resources

Event Details

4th Annual Evercore ISI HealthCONx Conference

December 2, 2021 at 12:10 PM EST

Click here for webcast

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2023 All Rights Reserved.

Footer Links

  • Contact
  • Privacy Policy
  • Terms of Use
LinkedIn Twitter